JP2016175913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016175913A5 JP2016175913A5 JP2016078990A JP2016078990A JP2016175913A5 JP 2016175913 A5 JP2016175913 A5 JP 2016175913A5 JP 2016078990 A JP2016078990 A JP 2016078990A JP 2016078990 A JP2016078990 A JP 2016078990A JP 2016175913 A5 JP2016175913 A5 JP 2016175913A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- seq
- mouse
- modified human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 claims 1
- 150000004676 glycans Chemical group 0.000 claims 1
- 230000005660 hydrophilic surface Effects 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000005661 hydrophobic surface Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36393310P | 2010-07-13 | 2010-07-13 | |
| US61/363,933 | 2010-07-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519804A Division JP6353654B2 (ja) | 2010-07-13 | 2011-07-13 | 抗血管新生剤及びこのような薬剤の使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016175913A JP2016175913A (ja) | 2016-10-06 |
| JP2016175913A5 true JP2016175913A5 (enExample) | 2017-02-16 |
Family
ID=44629339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519804A Active JP6353654B2 (ja) | 2010-07-13 | 2011-07-13 | 抗血管新生剤及びこのような薬剤の使用方法 |
| JP2016078990A Pending JP2016175913A (ja) | 2010-07-13 | 2016-04-11 | 抗血管新生剤及びこのような薬剤の使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519804A Active JP6353654B2 (ja) | 2010-07-13 | 2011-07-13 | 抗血管新生剤及びこのような薬剤の使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9175063B2 (enExample) |
| EP (2) | EP3381462B1 (enExample) |
| JP (2) | JP6353654B2 (enExample) |
| CN (1) | CN103002904B (enExample) |
| AU (5) | AU2011279155B2 (enExample) |
| CA (1) | CA2804753C (enExample) |
| DK (1) | DK2593127T3 (enExample) |
| ES (2) | ES2674409T3 (enExample) |
| HU (1) | HUE040205T2 (enExample) |
| PL (1) | PL2593127T3 (enExample) |
| PT (2) | PT3381462T (enExample) |
| WO (1) | WO2012009471A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3381462B1 (en) * | 2010-07-13 | 2022-06-08 | Georgia State University Research Foundation | Anti-angiogenic agent and method of using such agent |
| WO2016144815A1 (en) * | 2015-03-06 | 2016-09-15 | Georgia State University Research Foundation, Inc. | Integrin-targeting protein and methods of use thereof |
| CN110498851B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物及应用 |
| CN108148117A (zh) * | 2017-12-26 | 2018-06-12 | 张艳雪 | 一种抗菌肽的蛋白质结构特性及其研究方法 |
| WO2025250689A1 (en) * | 2024-05-28 | 2025-12-04 | Georgia State University Research Foundation | Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008187A1 (en) * | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| CA2497628A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
| WO2005077018A2 (en) * | 2004-02-06 | 2005-08-25 | Astellas Us Llc | Methods of treating skin disorders |
| US9339559B2 (en) * | 2005-09-09 | 2016-05-17 | Georgia State University Research Foundation, Inc. | Targeted contrast agents and methods for targeting contrast agents |
| US20110097742A1 (en) * | 2008-04-02 | 2011-04-28 | Jenny Jie Yang | Contrast agents, methods for preparing contrast agents, and methods of imaging |
| US8540967B2 (en) * | 2008-09-08 | 2013-09-24 | Hoffman/Barrett, L.L.C. | Porphyrazine optical and dual optical/MR contrast and therapeutic agents |
| EP3381462B1 (en) * | 2010-07-13 | 2022-06-08 | Georgia State University Research Foundation | Anti-angiogenic agent and method of using such agent |
-
2011
- 2011-07-13 EP EP18168598.3A patent/EP3381462B1/en active Active
- 2011-07-13 AU AU2011279155A patent/AU2011279155B2/en active Active
- 2011-07-13 CA CA2804753A patent/CA2804753C/en active Active
- 2011-07-13 EP EP11738546.8A patent/EP2593127B1/en active Active
- 2011-07-13 CN CN201180034591.9A patent/CN103002904B/zh active Active
- 2011-07-13 ES ES11738546.8T patent/ES2674409T3/es active Active
- 2011-07-13 PT PT181685983T patent/PT3381462T/pt unknown
- 2011-07-13 PT PT117385468T patent/PT2593127T/pt unknown
- 2011-07-13 JP JP2013519804A patent/JP6353654B2/ja active Active
- 2011-07-13 ES ES18168598T patent/ES2923430T3/es active Active
- 2011-07-13 US US13/739,241 patent/US9175063B2/en active Active
- 2011-07-13 DK DK11738546.8T patent/DK2593127T3/en active
- 2011-07-13 HU HUE11738546A patent/HUE040205T2/hu unknown
- 2011-07-13 PL PL11738546T patent/PL2593127T3/pl unknown
- 2011-07-13 WO PCT/US2011/043907 patent/WO2012009471A1/en not_active Ceased
-
2015
- 2015-10-30 US US14/928,890 patent/US11578114B2/en active Active
-
2016
- 2016-04-11 JP JP2016078990A patent/JP2016175913A/ja active Pending
-
2017
- 2017-02-20 AU AU2017201133A patent/AU2017201133A1/en not_active Abandoned
-
2019
- 2019-03-29 AU AU2019202174A patent/AU2019202174B2/en active Active
-
2021
- 2021-02-24 AU AU2021201207A patent/AU2021201207A1/en not_active Abandoned
-
2023
- 2023-04-26 AU AU2023202513A patent/AU2023202513A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| WO2016037154A8 (en) | Recombinant hiv-1 envelope proteins and their use | |
| WO2013044203A3 (en) | Novel influenza hemagglutinin protein-based vaccines | |
| WO2014160490A8 (en) | Antibody formulations | |
| HRP20171703T1 (hr) | Predfuzijski antigeni rsv f | |
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| IN2015DN02546A (enExample) | ||
| JP2013172734A5 (enExample) | ||
| BR112014020694A2 (pt) | proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a | |
| NZ725079A (en) | Transgene genetic tags and methods of use | |
| IL236650B (en) | Immunogenic combination, nucleic acids or vectors encoding it, host cells or compositions comprising them, and therapeutic uses thereof, process of producing an infectious virus and method for recombinant production of the mycobacterial antigens | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| WO2018020324A3 (en) | Virus-like particles with high-density coating for inducing the expression of antibodies | |
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| RU2015155821A (ru) | Вакцины против малярии | |
| MX375778B (es) | Variantes mejoradas de enzimas. | |
| HRP20191166T1 (hr) | Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus | |
| WO2015195218A8 (en) | Polyvalent influenza virus-like particles (vlps) and use as vaccines | |
| JP2012102105A5 (enExample) | ||
| JP2015511599A5 (enExample) | ||
| PH12016502554B1 (en) | A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection | |
| JP2024530047A5 (enExample) | ||
| JP2015518819A5 (enExample) |